Losmapimod (BioDeep_00000180534)
human metabolite blood metabolite
代谢物信息卡片
化学式: C22H26FN3O2 (383.2008948)
中文名称: Losmapimod
谱图信息:
最多检出来源 Homo sapiens(blood) 37.5%
分子结构信息
SMILES: CC1=C(C=C(C=C1F)C(=O)NC1CC1)C1=CC=C(C=N1)C(=O)NCC(C)(C)C
InChI: InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)
描述信息
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2149 - Mitogen-Activated Protein Kinase Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:131167
- PubChem: 11552706
- HMDB: HMDB0254167
- DrugBank: DB12270
- ChEMBL: CHEMBL1088752
- Wikipedia: Losmapimod
- CAS: 585543-15-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Michelle L Mellion, Lucienne Ronco, Cecile L Berends, Lisa Pagan, Sander Brooks, Michiel J van Esdonk, Emilie M J van Brummelen, Adefowope Odueyungbo, Lorin A Thompson, Michelle Hage, Umesh A Badrising, Shane Raines, William G Tracewell, Baziel van Engelen, Diego Cadavid, Geert J Groeneveld. Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement.
British journal of clinical pharmacology.
2021 12; 87(12):4658-4669. doi:
10.1111/bcp.14884. [PMID: 33931884] - Marie Fisk, Joseph Cheriyan, Divya Mohan, Julia Forman, Kaisa M Mäki-Petäjä, Carmel M McEniery, Jonathan Fuld, James H F Rudd, Nicholas S Hopkinson, David A Lomas, John R Cockcroft, Ruth Tal-Singer, Michael I Polkey, Ian B Wilkinson. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
PloS one.
2018; 13(3):e0194197. doi:
10.1371/journal.pone.0194197. [PMID: 29566026] - Xue-Mei Zhang, Li Zhang, Guili Wang, Wenxiu Niu, Zhijie He, Li Ding, Jie Jia. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition.
Neurochemistry international.
2015 Nov; 90(?):1-8. doi:
10.1016/j.neuint.2015.06.010. [PMID: 26116440] - Hiroko Ino, Naoki Takahashi, Takumi Terao, Harue Igarashi, Nobuaki Sarai. Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteers.
Clinical pharmacology in drug development.
2015 07; 4(4):262-9. doi:
10.1002/cpdd.190. [PMID: 27136906] - Keisha L Gibson, Dorey Glenn, Maria E Ferris. Back to the future: therapies for idiopathic nephrotic syndrome.
Blood purification.
2015; 39(1-3):105-9. doi:
10.1159/000368951. [PMID: 25659288] - Henrik Watz, Helen Barnacle, Benjamin F Hartley, Robert Chan. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
The Lancet. Respiratory medicine.
2014 Jan; 2(1):63-72. doi:
10.1016/s2213-2600(13)70200-5. [PMID: 24461903] - April M Barbour, Lea Sarov-Blat, Gengqian Cai, Michael J Fossler, Dennis L Sprecher, Johann Graggaber, Adam T McGeoch, Jo Maison, Joseph Cheriyan. Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.
British journal of clinical pharmacology.
2013 Jul; 76(1):99-106. doi:
10.1111/bcp.12063. [PMID: 23215699] - Shuying Yang, Misba Beerahee. Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.
European journal of clinical pharmacology.
2013 Jun; 69(6):1261-7. doi:
10.1007/s00228-012-1469-1. [PMID: 23325437] - Shuying Yang, Pauline Lukey, Misba Beerahee, Frank Hoke. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
Clinical pharmacokinetics.
2013 Mar; 52(3):187-98. doi:
10.1007/s40262-012-0025-6. [PMID: 23254770] - Maysoon Elkhawad, James H F Rudd, Lea Sarov-Blat, Gengqian Cai, Richard Wells, L Ceri Davies, David J Collier, Michael S Marber, Robin P Choudhury, Zahi A Fayad, Ahmed Tawakol, Fergus V Gleeson, John J Lepore, Bill Davis, Robert N Willette, Ian B Wilkinson, Dennis L Sprecher, Joseph Cheriyan. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.
JACC. Cardiovascular imaging.
2012 Sep; 5(9):911-22. doi:
10.1016/j.jcmg.2012.02.016. [PMID: 22974804] - David A Lomas, David A Lipson, Bruce E Miller, Lisa Willits, Oliver Keene, Helen Barnacle, Neil C Barnes, Ruth Tal-Singer. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.
Journal of clinical pharmacology.
2012 Mar; 52(3):416-24. doi:
10.1177/0091270010397050. [PMID: 22090363] - Robert N Willette, Marianne E Eybye, Alan R Olzinski, David J Behm, Nambi Aiyar, Kristeen Maniscalco, Ross G Bentley, Robert W Coatney, Shufang Zhao, Timothy D Westfall, Chris P Doe. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
The Journal of pharmacology and experimental therapeutics.
2009 Sep; 330(3):964-70. doi:
10.1124/jpet.109.154443. [PMID: 19556450]